Why the study?
Treatment patterns, outcomes by line of treatment, and healthcare resource utilization in patients with metastatic synovial sarcoma needed to be described.
What are the treatment patterns, outcomes, and healthcare resource utilization in patients with metastatic synovial sarcoma?
What are the treatment patterns, outcomes, and healthcare resource utilization in patients with metastatic synovial sarcoma?
This study highlights the poor overall survival and high healthcare resource utilization in patients with metastatic synovial sarcoma, particularly in later lines of therapy.
Aim: Describing the treatment patterns, outcomes by line of treatment (LOT), and healthcare resource utilization (HCRU) in patients with metastatic synovial sarcoma (mSS). Patients & methods: In this descriptive, non-interventional, retrospective cohort study, physicians from five European countries reported on patients with recent pharmacological treatment for mSS. Results: Among 296 patients with mSS, 86.1, 38.9 and 8.4% received 1 LOT (1L), 2 LOTs (2L) and 3+ LOTs (L3+), respectively. Common regimens were doxorubicin/ifosfamide-based (37.4%) for 1L and trabectedin-based for 2L (29.7%). For 1L, median time to next treatment was 13.1 and 6.0 months for living and deceased patients, respectively. Median OS was 22.0, 6.0 and 4.9 months in all patients, 2L and 3L, respectively. HCRU data showed median one inpatient hospital admission, 3 days in hospital and four outpatient visits yearly. Conclusion: This large-scale study documents high unmet needs in patients previously treated for mSS and for more effective therapies.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Future Oncology